SERPINC1

Summary

SERPINC1 (serpin family C member 1, HGNC:775) is a protein-coding gene on chromosome 1q25.1, encoding Antithrombin-III (P01008). Most important serine protease inhibitor in plasma that regulates the blood coagulation cascade.

The protein encoded by this gene, antithrombin III, is a plasma protease inhibitor and a member of the serpin superfamily. This protein inhibits thrombin as well as other activated serine proteases of the coagulation system, and it regulates the blood coagulation cascade. The protein includes two functional domains: the heparin binding-domain at the N-terminus of the mature protein, and the reactive site domain at the C-terminus. The inhibitory activity is enhanced by the presence of heparin. Numerous mutations have been identified for this gene, many of which are known to cause antithrombin-III deficiency which constitutes a strong risk factor for thrombosis. A reduction in the serum level of this protein is associated with severe cases of Coronavirus Disease 19 (COVID-19).

Source: NCBI Gene 462 — RefSeq curated summary.

At a glance

• Gene–disease (curated): hereditary antithrombin deficiency (Definitive, ClinGen)
• GWAS associations: 2
• Clinical variants (ClinVar): 480 total — 95 pathogenic, 67 likely-pathogenic
• Phenotypes (HPO): 20
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_000488

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:775
Approved symbol	SERPINC1
Name	serpin family C member 1
Location	1q25.1
Locus type	gene with protein product
Status	Approved
Aliases	ATIII, MGC22579
Ensembl gene	ENSG00000117601
Ensembl biotype	protein_coding
OMIM	107300
Entrez	462

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 12 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000367698, ENST00000487183, ENST00000494024, ENST00000874322, ENST00000874323, ENST00000874324, ENST00000874325, ENST00000874326, ENST00000874327, ENST00000874328, ENST00000874329, ENST00000874330, ENST00000874331, ENST00000874332

RefSeq mRNA: 7 — MANE Select: NM_000488 NM_000488, NM_001365052, NM_001386302, NM_001386303, NM_001386304, NM_001386305, NM_001386306

CCDS: CCDS1313

Canonical transcript exons

ENST00000367698 — 7 exons

Exon	Start	End
ENSE00000789908	173909552	173909942
ENSE00000789909	173910754	173910891
ENSE00001383315	173907450	173907514
ENSE00001876994	173903800	173904065
ENSE00001944151	173917219	173917327
ENSE00003578986	173914553	173914919
ENSE00003644352	173911799	173912014

Expression profiles

Bgee: expression breadth ubiquitous, 153 present calls, max score 99.73.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 11.3159 / max 5017.9498, expressed in 63 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
15971	6.0410	47
15970	4.2541	46
15974	0.3569	11
15967	0.3218	9
15972	0.1954	11
15975	0.0473	9
15969	0.0467	9
15973	0.0437	8
15968	0.0090	4

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lobe of liver	UBERON:0001114	99.73	gold quality
liver	UBERON:0002107	99.72	gold quality
adrenal tissue	UBERON:0018303	62.15	gold quality
colonic epithelium	UBERON:0000397	61.46	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	61.22	gold quality
lower esophagus mucosa	UBERON:0035834	61.20	gold quality
stromal cell of endometrium	CL:0002255	61.04	gold quality
adult mammalian kidney	UBERON:0000082	60.56	gold quality
oocyte	CL:0000023	58.33	gold quality
islet of Langerhans	UBERON:0000006	57.44	gold quality
kidney	UBERON:0002113	57.22	gold quality
renal glomerulus	UBERON:0000074	56.22	gold quality
nephron tubule	UBERON:0001231	55.71	gold quality
metanephric glomerulus	UBERON:0004736	55.26	gold quality
kidney epithelium	UBERON:0004819	54.58	gold quality
gastrocnemius	UBERON:0001388	54.55	gold quality
mucosa of stomach	UBERON:0001199	54.29	gold quality
metanephros	UBERON:0000081	53.86	silver quality
blood	UBERON:0000178	53.16	gold quality
paraflocculus	UBERON:0005351	52.96	gold quality
cortex of kidney	UBERON:0001225	52.38	gold quality
muscle of leg	UBERON:0001383	51.98	gold quality
right coronary artery	UBERON:0001625	51.82	gold quality
descending thoracic aorta	UBERON:0002345	51.62	gold quality
quadriceps femoris	UBERON:0001377	51.55	gold quality
muscle organ	UBERON:0001630	51.19	gold quality
pancreas	UBERON:0001264	51.08	gold quality
granulocyte	CL:0000094	51.07	silver quality
lower esophagus	UBERON:0013473	50.95	gold quality
lower esophagus muscularis layer	UBERON:0035833	50.91	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-GEOD-130473	yes	2859.31
E-HCAD-9	yes	54.72
E-MTAB-10553	yes	31.71
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ATF4, CEBPA, FOXA1, FOXA2, HNF4A, NR2F1, RXRA, SP1, THRA, THRB

Literature-anchored findings (GeneRIF, showing 40)

• We report 5 children from 3 families with homozygous antithrombin deficiency type II affecting the heparin binding site (99 Leu to Phe mutation). (PMID:11686316)
• The single base substitution of G to A at nucleotide 2709 was found in a proband with a family history of venous thrombosis. This results in a substitution of 82 Ser by Asn, creating a new glycosylation site causing type I antithrombin deficiency. (PMID:11686319)
• The karyotype showed 46XY, del(1)(q23q31.2), the antithrombin III (AT3, 1q23-q25.1) serum level and activity were half of normal. (PMID:11754060)
• A specific pentasaccharide sequence (H5) in high affinity heparin induces a conformational change in antithrombin that is particularly important for factor Xa (fXa) inhibition (factor Xa) (PMID:11854268)
• Antithrombin prevents endotoxin-induced hypotension by inhibiting the induction of nitric oxide synthase in rat lung. (PMID:11861278)
• Molecular biological basis and diagnosis of hereditary defects (review) (PMID:12193972)
• a new natural antithrombin mutation that confirms the critical contribution of lysine 114 to the binding of the core heparin pentasaccharide, with the replacement of lysine 114 by glutamate causing a complete loss in affinity (PMID:12353073)
• Arg is required in position 129 for high-affinity pentasaccharide binding of heparin to antithrombin, whereas Lys125 and Lys114 do not participate in intramolecular interactions of this type and can be acceptably replaced with Arg. (PMID:12369826)
• Data show that anti-thrombin is widely expressed in prostate cancer but is gradually lost in tumors of high Gleason grade. (PMID:12466122)
• hydrophobic residues Phe-122 and Phe-121 play a critical role in heparin binding and activation of antithrombin (PMID:12556442)
• A new antithrombin mutation, Phe229Leu, spontaneously polymerized in the proband’s circulation, causing cerebral venous thrombosis. Molecular modeling suggested how the mutation might destabilize the protein and favor polymerization. (PMID:12595305)
• study of the possibility that all pentasaccharide AT-binding sequences in antithrombin-heparin complex may catalyze factor Xa inhibition (PMID:12695507)
• Five novel and two previously reported point mutations in the antithrombin gene causing venous thrombosis were identified; the novel L409P mutation is a type 2 pleiotropic effects (PE) deficiency and it is highly conserved among other serpins. (PMID:12894857)
• findings suggest that antithrombin exosites responsible for enhancing the rates of factor Xa and factor IXa inhibition in the conformationally activated inhibitor lie in strand 3 of beta-sheet C of the serpin (PMID:14532267)
• endotoxin-induced adhesion of leukocytes to endothelium can be reversed by ligation of syndecan-4 with antithrombin’s heparin-binding site (PMID:14652650)
• identified two missense mutations affecting the shutter region of ATIII: P80S and G424R; the mutant ATIII is an inactive disulfide-linked dimer whose properties are consistent with head-to-head insertion of the reactive loop (PMID:15140129)
• Renal hypertension was caused by renal artery obstruction due to thrombus formation. This thrombus formation was attributed to antithrombin deficiency caused by a novel SERPINCI gene mutation (AT III Akita, M352R). (PMID:15338392)
• hAT3 might increase hepatic tissue levels of PGI2 via enhancement of hepatic I/R-induced activation of capsaicin-sensitive sensory neurons, thereby reducing liver injury in rats (PMID:15630490)
• clinical and biological features of heterozygotes who carry the N187D or N187K mutations; also investigated AT thermostability as well as the presence of latent or polymerized AT in plasma (PMID:15630491)
• The two mutated antithrombins were the same as that of wild type, but the specific activity of the E381del mutant decreased significantly compared with that of wild type. (PMID:15733967)
• This review assembles the available experimental and clinical data on biological mechanisms of antithrombin in inflammatory coagulation activation. (PMID:16542481)
• 22 novel SERPINC1 mutations are associated with antithrombin deficiency. (PMID:16705712)
• These results suggest that heparin-binding proteins influence the conformational equilibrium of iduronic acid residues that are directly or indirectly involved in binding. (PMID:16796563)
• tyrosine 131 in the native conformation of antithrombin III activates it for factor Xa inhibition (PMID:16940049)
• This study reports that the poor inhibitory activity of the circulating of AT is partially conferred by intramolecular contacts that restrain the RCL, orient the P1 residue away from attacking proteases, and block the exosite used in protease recognition. (PMID:16973611)
• Antithrombin A384S mutation is a prevalent genetic risk factor for venous thrombosis and is the most frequent cause of antithrombin deficiency in white populations. (PMID:17244682)
• pulmonary endothelium contributes to the antithrombin III metabolism with a 0.023 breakdown rate; The data support the hypothesis of a main endothelial catabolism of antithrombin III (PMID:17413759)
• findings suggested that FS-3Stop and Met-32Thr mutations are responsible for type I antithrombin deficiency, whereas Ser116Pro and Ala59Val mutations contribute to type II antithrombin deficiency (PMID:17492649)
• REVIEW OF AT3 BINDING INTERACTIONS, HEREDITARY AT3 DEFICIENCY, LOW LEVEL IN DIC (PMID:17597998)
• Report novel antithrombin heparin-binding site variant associated with low thrombotic risk. (PMID:17849067)
• High antithrombin III in cerebrospinal fluid is associated with CNS lymphoma (PMID:18056677)
• A previously unreported heterozygous large deletion spanning exons 1-6 of the SERPINC1 gene was responsible for hereditary antithrombin deficiency in a Korean family. (PMID:18208532)
• Identification in human milk of complexes of matriptase with ATIII, A1AT, or A2AP, provides evidence that the proteolytic activity of matriptase, from cells that express no or low levels of HAI-1, may be controlled by secreted serpins. (PMID:18550704)
• crystallographic structure of a stable serpin dimer which reveals a domain swap of more than 50 residues, including two long antiparallel beta-strands inserting in the centre of the principal beta-sheet of the neighbouring monomer (PMID:18923394)
• Prevalence of genetic mutations in SERPINC1 in Japanese patients with venous thrombosis is reported. (PMID:18954896)
• functional effect of the rs2227589 polymorphism not explained by its linkage with the promoter polymorphism that supports the moderate thrombotic risk associated with the A allele. (PMID:19229049)
• The study shows that Antithrombin Cambridge II (A384S) significantly increases the risk of myocardial infarction . (PMID:19277409)
• AT-III directly acts on platelets and suppresses ADP-induced platelet granule secretion due to inhibiting HSP27 phosphorylation via p44/p42 MAPK and p38 MAPK. (PMID:19631608)
• These results indicate that P2-Gly plays a key role in determining the S2 sub-site specificity and target protease selectivity of AT in circulation. (PMID:19715676)
• Data show that large deletions explain almost half of otherwise unexplained type I AT-inherited deficiency cases. (PMID:19760264)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	serpinc1	ENSDARG00000042684
mus_musculus	Serpinc1	ENSMUSG00000026715
rattus_norvegicus	Serpinc1	ENSRNOG00000002783

Paralogs (36): SERPINB1 (ENSG00000021355), SERPINB3 (ENSG00000057149), SERPIND1 (ENSG00000099937), SERPINA4 (ENSG00000100665), SERPINE1 (ENSG00000106366), SERPINI2 (ENSG00000114204), SERPINA7 (ENSG00000123561), SERPINB6 (ENSG00000124570), SERPINF1 (ENSG00000132386), AGT (ENSG00000135744), SERPINE2 (ENSG00000135919), SERPINA10 (ENSG00000140093), SERPING1 (ENSG00000149131), SERPINH1 (ENSG00000149257), SERPINI1 (ENSG00000163536), SERPINA12 (ENSG00000165953), SERPINB7 (ENSG00000166396), SERPINB8 (ENSG00000166401), SERPINB12 (ENSG00000166634), SERPINF2 (ENSG00000167711), SERPINA9 (ENSG00000170054), SERPINA6 (ENSG00000170099), SERPINB9 (ENSG00000170542), SERPINA11 (ENSG00000186910), SERPINA5 (ENSG00000188488), SERPINA3 (ENSG00000196136), SERPINA1 (ENSG00000197249), SERPINB2 (ENSG00000197632), SERPINB13 (ENSG00000197641), SERPINB11 (ENSG00000206072), SERPINB4 (ENSG00000206073), SERPINB5 (ENSG00000206075), HMSD (ENSG00000221887), SERPINB10 (ENSG00000242550), SERPINE3 (ENSG00000253309), SERPINA2 (ENSG00000258597)

Protein

Protein identifiers

Antithrombin-III — P01008 (reviewed: P01008)

Alternative names: Serpin C1

All UniProt accessions (2): A0A2S0BDD1, P01008

UniProt curated annotations — full annotation on UniProt →

Function. Most important serine protease inhibitor in plasma that regulates the blood coagulation cascade. AT-III inhibits thrombin, matriptase-3/TMPRSS7, as well as factors IXa, Xa and XIa. Its inhibitory activity is greatly enhanced in the presence of heparin.

Subunit / interactions. Forms protease inhibiting heterodimer with TMPRSS7.

Subcellular location. Secreted. Extracellular space.

Tissue specificity. Found in plasma.

Post-translational modifications. Phosphorylated by FAM20C in the extracellular medium.

Disease relevance. Antithrombin III deficiency (AT3D) [MIM:613118] An important risk factor for hereditary thrombophilia, a hemostatic disorder characterized by a tendency to recurrent thrombosis. Antithrombin-III deficiency is classified into 4 types. Type I: characterized by a 50% decrease in antigenic and functional levels. Type II: has defects affecting the thrombin-binding domain. Type III: alteration of the heparin-binding domain. Plasma AT-III antigen levels are normal in type II and III. Type IV: consists of miscellaneous group of unclassifiable mutations. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the serpin family.

RefSeq proteins (7): NP_000479, NP_001351981, NP_001373231, NP_001373232, NP_001373233, NP_001373234, NP_001373235 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000215	Serpin_fam	Family
IPR023795	Serpin_CS	Conserved_site
IPR023796	Serpin_dom	Domain
IPR033829	Antithrombin_3_serpin_domain	Domain
IPR036186	Serpin_sf	Homologous_superfamily
IPR042178	Serpin_sf_1	Homologous_superfamily
IPR042185	Serpin_sf_2	Homologous_superfamily

Pfam: PF00079

UniProt features (174 total): sequence variant 102, strand 26, helix 15, sequence conflict 8, turn 6, glycosylation site 4, disulfide bond 3, binding site 3, mutagenesis site 2, modified residue 2, signal peptide 1, chain 1, site 1

Structure

Experimental structures (PDB)

27 structures.

PDB	Method	Resolution (Å)
3KCG	X-RAY DIFFRACTION	1.7
2B5T	X-RAY DIFFRACTION	2.1
1TB6	X-RAY DIFFRACTION	2.5
1E04	X-RAY DIFFRACTION	2.6
1JVQ	X-RAY DIFFRACTION	2.6
1NQ9	X-RAY DIFFRACTION	2.6
2ANT	X-RAY DIFFRACTION	2.6
1E05	X-RAY DIFFRACTION	2.62
1OYH	X-RAY DIFFRACTION	2.62
1R1L	X-RAY DIFFRACTION	2.7
2BEH	X-RAY DIFFRACTION	2.7
1T1F	X-RAY DIFFRACTION	2.75
1DZG	X-RAY DIFFRACTION	2.8
1LK6	X-RAY DIFFRACTION	2.8
2B4X	X-RAY DIFFRACTION	2.8
2ZNH	X-RAY DIFFRACTION	2.8
4EB1	X-RAY DIFFRACTION	2.8
1DZH	X-RAY DIFFRACTION	2.85
1AZX	X-RAY DIFFRACTION	2.9
1BR8	X-RAY DIFFRACTION	2.9
1E03	X-RAY DIFFRACTION	2.9
2HIJ	X-RAY DIFFRACTION	2.9
1ANT	X-RAY DIFFRACTION	3
3EVJ	X-RAY DIFFRACTION	3
1SR5	X-RAY DIFFRACTION	3.1
1ATH	X-RAY DIFFRACTION	3.2
2GD4	X-RAY DIFFRACTION	3.3

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P01008-F1	85.34	0.70

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 425–426 (reactive bond)

Ligand- & substrate-binding residues (3): 81; 161; 177

Post-translational modifications (2): 63, 68

Disulfide bonds (3): 40–160, 53–127, 279–462

Glycosylation sites (4): 187, 224, 128, 167

Mutagenesis-validated functional residues (2):

Position	Phenotype
414	reduces interaction with thrombin by 99%.
414	reduces interaction with thrombin by 80%.

Function

Pathways and Gene Ontology

Reactome pathways

12 pathways

ID	Pathway
R-HSA-381426	Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
R-HSA-8957275	Post-translational protein phosphorylation
R-HSA-9769733	Fibrin formation
R-HSA-9769735	Initiation of coagulation cascade
R-HSA-9769739	Regulation of clotting cascade
R-HSA-9769743	Amplification and propagation of coagulation cascade
R-HSA-140837
R-HSA-140875
R-HSA-109582	Hemostasis
R-HSA-140877
R-HSA-392499	Metabolism of proteins
R-HSA-597592	Post-translational protein modification

MSigDB gene sets: 230 (showing top): GOBP_REGULATION_OF_WOUND_HEALING, GOBP_REGULATION_OF_COAGULATION, GNF2_GSTM1, GNF2_HPN, TGACCTY_ERR1_Q2, SHEPARD_BMYB_MORPHOLINO_DN, COUP_01, GOBP_WOUND_HEALING, VART_KSHV_INFECTION_ANGIOGENIC_MARKERS_UP, HOSHIDA_LIVER_CANCER_SUBCLASS_S3, GOBP_REGULATION_OF_RESPONSE_TO_WOUNDING, GNF2_LCAT, INGRAM_SHH_TARGETS_UP, HSIAO_LIVER_SPECIFIC_GENES, GOBP_REGULATION_OF_RESPONSE_TO_STRESS

GO Biological Process (3): blood coagulation (GO:0007596), regulation of blood coagulation (GO:0030193), hemostasis (GO:0007599)

GO Molecular Function (6): protease binding (GO:0002020), serine-type endopeptidase inhibitor activity (GO:0004867), heparin binding (GO:0008201), identical protein binding (GO:0042802), protein binding (GO:0005515), peptidase inhibitor activity (GO:0030414)

GO Cellular Component (7): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615), endoplasmic reticulum lumen (GO:0005788), plasma membrane (GO:0005886), extracellular matrix (GO:0031012), extracellular exosome (GO:0070062), blood microparticle (GO:0072562)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Coagulation pathway	4
Metabolism of proteins	2
Post-translational protein modification	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
hemostasis	1
wound healing	1
coagulation	1
blood coagulation	1
regulation of response to external stimulus	1
regulation of coagulation	1
regulation of wound healing	1
regulation of hemostasis	1
regulation of body fluid levels	1
enzyme binding	1
serine-type endopeptidase activity	1
endopeptidase inhibitor activity	1
glycosaminoglycan binding	1
sulfur compound binding	1
protein binding	1
binding	1
enzyme inhibitor activity	1
peptidase activity	1
peptidase regulator activity	1
endoplasmic reticulum	1
intracellular organelle lumen	1
membrane	1
cell periphery	1
external encapsulating structure	1
extracellular vesicle	1
extracellular region	1

Protein interactions and networks

STRING

1718 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SERPINC1	F2	P00734	980
SERPINC1	PLG	P00747	960
SERPINC1	F3	P13726	958
SERPINC1	TFPI	P10646	935
SERPINC1	VTN	P01141	924
SERPINC1	PLAT	P00750	915
SERPINC1	THBD	P07204	913
SERPINC1	A2M	P01023	912
SERPINC1	F7	P08709	882
SERPINC1	F9	P00740	864
SERPINC1	KLK4	Q9Y5K2	864
SERPINC1	ALB	P02768	863
SERPINC1	F8	P00451	809
SERPINC1	PF4V1	P10720	803
SERPINC1	FGA	P02671	800

IntAct

50 interactions, top by confidence:

A	B	Type	Score
RNF146	TNKS	psi-mi:“MI:0914”(association)	0.790
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
GPX7	GAK	psi-mi:“MI:0914”(association)	0.640
CFTR	HAX1	psi-mi:“MI:0914”(association)	0.610
SERPINC1	SERPINC1	psi-mi:“MI:0407”(direct interaction)	0.560
DDX31	IGLL5	psi-mi:“MI:0914”(association)	0.530
FCGRT	GOLIM4	psi-mi:“MI:0914”(association)	0.530
SERPINC1	BTD	psi-mi:“MI:0914”(association)	0.530
ING4	KAT7	psi-mi:“MI:0914”(association)	0.530
LGALS1	PODXL	psi-mi:“MI:0914”(association)	0.530
SPSB4	ARHGEF10	psi-mi:“MI:0914”(association)	0.530
C1QBP	F2	psi-mi:“MI:0914”(association)	0.460
SERPINC1	FAM20C	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
SERPINC1	F9	psi-mi:“MI:0407”(direct interaction)	0.440
SERPINC1	F2	psi-mi:“MI:0915”(physical association)	0.400
PLCG1	SERPINC1	psi-mi:“MI:0915”(physical association)	0.400
	CD5L	psi-mi:“MI:0915”(physical association)	0.400
	LECT2	psi-mi:“MI:0915”(physical association)	0.400
HR	SERPINC1	psi-mi:“MI:0914”(association)	0.350

BioGRID (65): TUBB8 (Affinity Capture-MS), TUBB1 (Affinity Capture-MS), TEX15 (Affinity Capture-MS), OS9 (Affinity Capture-MS), ISCA2 (Affinity Capture-MS), SUCLG1 (Affinity Capture-MS), BTD (Affinity Capture-MS), PFAS (Co-fractionation), TUBB1 (Affinity Capture-MS), TEX15 (Affinity Capture-MS), SERPINC1 (Affinity Capture-MS), BTD (Affinity Capture-MS), SERPINC1 (Affinity Capture-MS), SUCLG1 (Affinity Capture-MS), OS9 (Affinity Capture-MS)

ESM2 similar proteins: A0A090BX51, A0A0K8RCY5, A0A0K8RJ89, A0A0K8RJV9, A0A7H0DNF9, B3RFC3, E2RVI8, O73860, O75635, P01008, P01012, P01014, P05120, P07092, P07093, P07385, P0DSW3, P12388, P13909, P14754, P15059, P19104, P20961, P22777, P22922, P42926, P50449, P68565, P68566, P79335, P80034, Q06B72, Q06B74, Q06B75, Q07235, Q27085, Q27086, Q5MGH0, Q5R5A3, Q6J201

Diamond homologs: A0A090BX51, A0A0K8RCY5, A0A0K8RJ89, A0A0K8RJV9, A5PJK0, A9RA96, B0CMB0, B1MTB7, B1MTC3, B2KI30, B3RFC3, B4USX2, E2RVI8, O02739, O08800, O35684, O54757, O54758, O54759, O54760, O73790, O73860, O75635, O75830, P01008, P01011, P01012, P01014, P05120, P05619, P12388, P17475, P19104, P22323, P22325, P22922, P23035, P29508, P29524, P30740

SIGNOR signaling

6 interactions.

A	Effect	B	Mechanism
SERPINC1	up-regulates	LRP1	binding
SERPINC1	“down-regulates activity”	F2	cleavage
SERPINC1	“down-regulates activity”	F11	cleavage
SERPINC1	“down-regulates activity”	F10	cleavage
SERPINC1	“down-regulates activity”	F12	cleavage
SERPINC1	“down-regulates activity”	F9	cleavage

Disease & clinical

Clinical variants and AI predictions

ClinVar

480 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	95
Likely pathogenic	67
Uncertain significance	160
Likely benign	107
Benign	19

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
100923	NM_000488.4(SERPINC1):c.1016G>A (p.Trp339Ter)	Pathogenic
1321887	NC_000001.11:g.173896668_173942868del	Pathogenic
1321892	NC_000001.11:g.173914640_173922032del	Pathogenic
1321893	NM_000488.4(SERPINC1):c.84_409-536del	Pathogenic
1321894	NM_000488.4(SERPINC1):c.408+948_763-386del	Pathogenic
1321895	NM_000488.4(SERPINC1):c.42-486_1154-846del	Pathogenic
1321900	NC_000001.11:g.173916704_173935703del	Pathogenic
1321902	NM_000488.4(SERPINC1):c.763-379_1084del	Pathogenic
1321903	NM_000488.4(SERPINC1):c.1154-898_1218+410del	Pathogenic
1321904	NM_000488.4(SERPINC1):c.1154-40_1218+127dup	Pathogenic
1321905	NM_000488.4(SERPINC1):c.1154-324_1218+475dup	Pathogenic
1321907	NM_000488.4(SERPINC1):c.41+297_55del	Pathogenic
1321909	NC_000001.11:g.173905922_173905923ins[NC_000006.11:56893618_56896059]	Pathogenic
1321911	NC_000001.11:g.173879820_173925989del	Pathogenic
1330290	NM_000488.4(SERPINC1):c.436A>G (p.Lys146Glu)	Pathogenic
1335876	NC_000001.11:g.173908412_173919816dup	Pathogenic
1434089	NM_000488.4(SERPINC1):c.381T>A (p.Cys127Ter)	Pathogenic
1456446	NM_000488.4(SERPINC1):c.607C>T (p.Gln203Ter)	Pathogenic
18004	NM_000488.4(SERPINC1):c.235C>T (p.Arg79Cys)	Pathogenic
18005	AT-III Roma	Pathogenic
18006	AT-III Trento	Pathogenic
18007	NM_000488.4(SERPINC1):c.1246G>C (p.Ala416Pro)	Pathogenic
18008	AT-III Fontainebleu	Pathogenic
18010	NM_000488.4(SERPINC1):c.1277C>T (p.Ser426Leu)	Pathogenic
18011	NM_000488.4(SERPINC1):c.218C>T (p.Pro73Leu)	Pathogenic
18012	NM_000488.4(SERPINC1):c.89T>A (p.Val30Glu)	Pathogenic
18013	AT-III Barcelona	Pathogenic
18014	NM_000488.4(SERPINC1):c.236G>A (p.Arg79His)	Pathogenic
18016	NM_000488.4(SERPINC1):c.1273C>T (p.Arg425Cys)	Pathogenic
18019	NM_000488.4(SERPINC1):c.1274G>A (p.Arg425His)	Pathogenic

SpliceAI

976 predictions. Top by Δscore:

Variant	Effect	Δscore
1:173907442:GTACT:G	donor_loss	1.0000
1:173907444:ACT:A	donor_loss	1.0000
1:173907445:CTC:C	donor_loss	1.0000
1:173907446:TCAC:T	donor_loss	1.0000
1:173907447:CAC:C	donor_loss	1.0000
1:173907448:ACCTC:A	donor_loss	1.0000
1:173907449:C:T	donor_loss	1.0000
1:173907512:TACC:T	acceptor_loss	1.0000
1:173907515:C:CG	acceptor_loss	1.0000
1:173907516:T:A	acceptor_loss	1.0000
1:173909540:T:TA	donor_gain	1.0000
1:173909938:AGGCC:A	acceptor_gain	1.0000
1:173909939:GGCC:G	acceptor_gain	1.0000
1:173909940:GCC:G	acceptor_gain	1.0000
1:173909941:CC:C	acceptor_gain	1.0000
1:173909941:CCC:C	acceptor_gain	1.0000
1:173909942:CC:C	acceptor_gain	1.0000
1:173909943:C:CC	acceptor_gain	1.0000
1:173909943:C:T	acceptor_gain	1.0000
1:173909943:CTG:C	acceptor_loss	1.0000
1:173909944:T:G	acceptor_loss	1.0000
1:173910806:T:TA	donor_gain	1.0000
1:173911795:TCAC:T	donor_loss	1.0000
1:173911797:ACCT:A	donor_loss	1.0000
1:173914554:T:TA	donor_gain	1.0000
1:173914916:CTTC:C	acceptor_gain	1.0000
1:173914917:TTC:T	acceptor_gain	1.0000
1:173914918:TC:T	acceptor_gain	1.0000
1:173914919:CC:C	acceptor_gain	1.0000
1:173914920:C:CC	acceptor_gain	1.0000

AlphaMissense

3067 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:173914619:A:C	S114R	0.998
1:173914619:A:T	S114R	0.998
1:173914621:T:G	S114R	0.998
1:173909936:A:G	W257R	0.996
1:173909936:A:T	W257R	0.996
1:173909934:C:A	W257C	0.995
1:173909934:C:G	W257C	0.995
1:173914585:C:G	A126P	0.995
1:173910769:G:C	N249K	0.994
1:173910769:G:T	N249K	0.994
1:173911893:C:G	R177P	0.994
1:173914560:A:G	L134P	0.994
1:173914587:C:T	G125D	0.994
1:173911950:A:G	L158P	0.993
1:173914584:G:T	A126D	0.993
1:173907481:A:T	V396D	0.992
1:173910782:A:G	L245P	0.992
1:173911841:A:C	S194R	0.992
1:173911841:A:T	S194R	0.992
1:173911843:T:G	S194R	0.992
1:173914588:C:G	G125R	0.992
1:173909605:A:G	L367P	0.991
1:173911886:A:C	F179L	0.991
1:173911886:A:T	F179L	0.991
1:173911888:A:G	F179L	0.991
1:173911890:A:G	L178P	0.991
1:173914603:C:G	A120P	0.991
1:173914713:A:G	L83P	0.991
1:173914602:G:T	A120D	0.989
1:173904044:C:G	A414P	0.988

dbSNP variants (sampled 300 via entrez): RS1000202171 (1:173910078 T>C,G), RS1000332785 (1:173904290 T>A), RS1000582649 (1:173908014 TAATA>T), RS1000949668 (1:173911362 A>G), RS1001057744 (1:173907678 A>C), RS1001156482 (1:173914357 A>G), RS1001555339 (1:173910275 T>C), RS1001654948 (1:173909315 T>A), RS1001880914 (1:173917165 T>C), RS1001992574 (1:173910573 T>C,G), RS1002022677 (1:173903632 C>A), RS1002105677 (1:173904787 A>G), RS1002424360 (1:173908529 TCTAATTA>T), RS1002517609 (1:173914757 T>G), RS1002618543 (1:173908360 G>A)

Disease associations

OMIM: gene MIM:107300 | disease phenotypes: MIM:613118, MIM:613254, MIM:120430

GenCC curated gene-disease

Disease	Classification	Inheritance
hereditary antithrombin deficiency	Definitive	Autosomal dominant

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
hereditary antithrombin deficiency	Definitive	SD

Mondo (4): hereditary antithrombin deficiency (MONDO:0013144), tuberous sclerosis 2 (MONDO:0013199), thrombocytopenia (MONDO:0002049), coloboma of optic nerve (MONDO:0007354)

Orphanet (4): Hereditary thrombophilia due to congenital antithrombin deficiency (Orphanet:82), Tuberous sclerosis complex (Orphanet:805), Morning glory disc anomaly (Orphanet:35737), Coloboma of optic disc (Orphanet:98947)

HPO phenotypes

20 total (21 of 20 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000007	Autosomal recessive inheritance
HP:0001976	Reduced antithrombin III activity
HP:0002204	Pulmonary embolism
HP:0002625	Deep venous thrombosis
HP:0002638	Superficial thrombophlebitis
HP:0004419	Recurrent thrombophlebitis
HP:0004420	Arterial thrombosis
HP:0004831	Recurrent thromboembolism
HP:0005268	Miscarriage
HP:0005305	Cerebral venous thrombosis
HP:0012636	Retinal venous occlusion
HP:0025324	Arterial occlusion
HP:0030242	Portal vein thrombosis
HP:0030243	Hepatic vein thrombosis
HP:0030248	Mesenteric venous thrombosis
HP:0031437	Pregnancy exposure
HP:0040226	Decreased level of heparin co-factor II
HP:0040246	Reduced antithrombin antigen
HP:0200067	Recurrent spontaneous abortion
HP:0000588	Optic disc coloboma

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST006944_27	Experiencing mood swings	4.000000e-08
GCST006979_962	Heel bone mineral density	2.000000e-12

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0008475	mood instability measurement
EFO:0009270	heel bone mineral density

MeSH disease descriptors (4)

Descriptor	Name	Tree numbers
D020152	Antithrombin III Deficiency	C15.378.100.100.075; C15.378.147.150; C15.378.925.075; C16.320.099.075
D013921	Thrombocytopenia	C15.378.140.855; C15.378.243.937
C535970	Coloboma of optic nerve (supp.)
C566021	Tuberous Sclerosis 2 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL1950 (SINGLE PROTEIN), CHEMBL2111449 (PROTEIN COMPLEX)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 3 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL5314374	IDRAPARINUX SODIUM	3	3

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs5877	Toxicity	3	carboplatin;gemcitabine	Non-Small Cell Lung Carcinoma;Thrombocytopenia

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs5877	SERPINC1	3	2.50	1	carboplatin;gemcitabine

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — Blood coagulation components

Most potent curated ligand interactions (2 total), top 2:

Ligand	Action	Affinity	Parameter
heparin	Activation	7.85	pKd
fondaparinux	Activation	7.49	pKd

Binding affinities (BindingDB)

6 measured of 6 human assays (6 total across all organisms); most potent 6 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
N-decyl-N-(3,4-dihydroxyphenyl)sulfonyl-3,4-dihydroxybenzenesulfonamide	IC50	44400 nM	US-9718760: Plasminogen activator inhibitor-1 inhibitors and methods of use thereof
N-(3,4-dihydroxyphenyl)sulfonyl-3,5-difluoro-4-hydroxy-N-octylbenzenesulfonamide	IC50	87000 nM	US-9718760: Plasminogen activator inhibitor-1 inhibitors and methods of use thereof
N-(3,4-dihydroxyphenyl)sulfonyl-N-dodecyl-3,4-dihydroxybenzenesulfonamide	IC50	547000 nM	US-9718760: Plasminogen activator inhibitor-1 inhibitors and methods of use thereof
3,4,5-trihydroxy-N-octylbenzamide	IC50	1.67e+06 nM	US-9718760: Plasminogen activator inhibitor-1 inhibitors and methods of use thereof
N-(3,5-difluoro-4-hydroxyphenyl)sulfonyl-3,5-difluoro-4-hydroxy-N-octylbenzenesulfonamide	IC50	2.33e+06 nM	US-9718760: Plasminogen activator inhibitor-1 inhibitors and methods of use thereof
N-benzyl-3,4-dihydroxybenzenesulfonamide	IC50	2.33e+06 nM	US-9718760: Plasminogen activator inhibitor-1 inhibitors and methods of use thereof

ChEMBL bioactivities

6 potent at pChembl≥5 of 6 total, top 6 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.00	Kd	1	nM	IDRAPARINUX SODIUM
8.72	Kd	1.9	nM	CHEMBL2303815
8.55	Kd	2.8	nM	CHEMBL2303814
8.15	Kd	7	nM	CHEMBL1909451
7.24	Kd	58	nM	CHEMBL609990
6.24	IC50	570	nM	CHEMBL51173

PubChem BioAssay actives

4 with measured affinity, of 59 total; 4 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
nonasodium;(2S,3S,4S,5R,6R)-6-[(2R,3R,4S,5R,6R)-6-[(2R,3S,4S,5R,6R)-2-carboxylato-4,5-dimethoxy-6-[(2R,3R,4S,5R,6S)-6-methoxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-4,5-dimethoxy-3-[(2R,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(sulfonatooxymethyl)oxan-2-yl]oxyoxane-2-carboxylate	527395: Binding affinity to antithrombin 3	kd	0.0010	uM
decasodium;(2R,3S,4S,5R,6R)-6-[(2S,3R,4S,5R,6S)-6-[(2S,3S,4S,5R,6R)-2-carboxylato-6-[(2S,3S,4S,5S,6S)-4,6-dimethoxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-4-methoxy-5-sulfonatooxyoxan-3-yl]oxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3-[(2R,3R,4R,5S,6S)-4,5-dimethoxy-3-(sulfonatoamino)-6-(sulfonatooxymethyl)oxan-2-yl]oxy-4,5-dimethoxyoxane-2-carboxylate	38738: Dissociation constant for Antithrombin-III	kd	0.0070	uM
decasodium;(3S,4R,6R)-3-[(2S,4S,5R)-5-[(2R,5S,6R)-6-carboxylato-5-[(2R,5S,6S)-4,5-dihydroxy-3-(sulfonatoamino)-6-(sulfonatooxymethyl)oxan-2-yl]oxy-3,4-dihydroxyoxan-2-yl]oxy-3,4-disulfonatooxy-6-(sulfonatooxymethyl)oxan-2-yl]oxy-6-[(2S,3S,6S)-4,6-dihydroxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-4-hydroxy-5-(sulfonatoamino)oxane-2-carboxylate	38738: Dissociation constant for Antithrombin-III	kd	0.0580	uM
N-[(2R)-3-(4-carbamimidoylphenyl)-1-oxo-1-piperidin-1-ylpropan-2-yl]-2-(naphthalen-2-ylsulfonylamino)acetamide	38735: Antithrombin III (ATIII)-mediated anti-Xa activity was determined	ic50	0.5700	uM

CTD chemical–gene interactions

73 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Ethinyl Estradiol	affects binding, decreases expression, affects cotreatment, decreases activity	8
ethinyl estradiol-desogestrel combination	decreases activity, decreases expression, increases expression	7
Heparin	decreases expression, affects binding, increases expression	4
Cyclosporine	decreases expression, increases expression	3
Aflatoxin B1	decreases expression, affects expression	3
Levonorgestrel	decreases expression, affects cotreatment, decreases activity	3
sodium arsenite	increases methylation, decreases expression	2
Gestodene	decreases activity, decreases expression, affects cotreatment	2
Acetaminophen	decreases expression	2
Benzo(a)pyrene	decreases expression	2
Contraceptives, Oral	decreases activity, affects response to substance	2
Estrogens	decreases activity, decreases expression	2
Hydrogen Peroxide	affects expression, increases expression	2
Tobacco Smoke Pollution	decreases expression, affects expression	2
testosterone enanthate	increases expression	1
methyleugenol	decreases expression	1
bisphenol A	affects expression	1
calcium heparin	increases activity	1
potassium perchlorate	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
norgestimate	affects cotreatment, decreases expression	1
cobaltous chloride	increases expression	1
nickel chloride	decreases expression	1
dienogest	affects cotreatment, decreases activity	1
benzo(e)pyrene	increases methylation	1
periodate-oxidized adenosine	affects expression	1
2,3-dimethoxy-1,4-naphthoquinone	decreases expression	1
ethinyl estradiol, levonorgestrel drug combination	decreases expression	1
estradiol, norethindrone drug combination	decreases expression	1
estradiol valerate-dienogest	affects cotreatment, decreases activity	1

ChEMBL screening assays

19 unique, capped per target: 19 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1072392	Binding	Inhibition of antithrombin-3 assessed as residual alpha-thrombin activity	Novel bis-arylsulfonamides and aryl sulfonimides as inactivators of plasminogen activator inhibitor-1 (PAI-1). — Bioorg Med Chem Lett

Cellosaurus cell lines

3 cell lines: 2 induced pluripotent stem cell, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A9YM	ZZUNEUi014-A	Induced pluripotent stem cell	Female
CVCL_C9LX	SFPHi001-A	Induced pluripotent stem cell	Female
CVCL_IR13	CHO-13D-35D	Transformed cell line	Female

Clinical trials (associated diseases)

257 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT02278575	PHASE4	WITHDRAWN	Atenativ Effect on Uterine Blood Flow and Preeclampsia
NCT00039858	PHASE4	COMPLETED	Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
NCT00239733	PHASE4	TERMINATED	Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection
NCT00907478	PHASE4	COMPLETED	Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP)
NCT01727401	PHASE4	TERMINATED	Thromboprophylaxis of Venous Thromboembolism in Acutely-ill Medical Inpatients With Thrombocytopenia
NCT02032134	PHASE4	TERMINATED	Protocol for the Infusion of Buffy Coat-derived Cryopreserved Platelets in Patients With Severe Thrombocytopenia
NCT02267993	PHASE4	COMPLETED	Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients
NCT03633019	PHASE4	UNKNOWN	High-dose Use of rhTPO in CIT Patients
NCT03688191	PHASE4	UNKNOWN	Study of Sirolimus in CTD-TP in China
NCT04906083	PHASE4	UNKNOWN	Avatrombopag in Patients With End-stage Liver Disease and Thrombocytopenia
NCT05217719	PHASE4	UNKNOWN	Effects of Recombinant Human Thrombopoietin on Platelet Levels in ICU Patients
NCT05255003	PHASE4	RECRUITING	STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis
NCT05382013	PHASE4	UNKNOWN	Efficacy and Safety of Avatrombopag for Treating TCP in HBV-ACLF Patients Receiving ALSS Treatment
NCT05944458	PHASE4	COMPLETED	Efficacy of Intravenous N-Acetylcysteine in Preventing Linezolid-Induced Thrombocytopenia in Critically Ill Patients
NCT06562738	PHASE4	RECRUITING	Clinical Study on Efficacy and Safety of Hetrombopag in the Preoperative Patients of Thrombocytopenia
NCT00110513	PHASE3	COMPLETED	Recombinant Human Antithrombin (rhAT) in Patients With Hereditary Antithrombin Deficiency Undergoing Surgery or Delivery
NCT04918173	PHASE3	RECRUITING	Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery
NCT06096116	PHASE3	RECRUITING	Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass
NCT00037791	PHASE3	COMPLETED	Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
NCT00039910	PHASE3	COMPLETED	Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
NCT00073580	PHASE3	COMPLETED	Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)
NCT00102323	PHASE3	COMPLETED	AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy
NCT00102336	PHASE3	COMPLETED	AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy
NCT00116688	PHASE3	COMPLETED	Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
NCT00128713	PHASE3	COMPLETED	Optimal Platelet Dose Strategy for Management of Thrombocytopenia
NCT00151866	PHASE3	COMPLETED	Efficacy of Transfusions With Platelets Stored in Platelet Additive Solution II Versus Plasma
NCT00261924	PHASE3	COMPLETED	Efficacy and Safety Study of Platelets Treated for Pathogen Inactivation and Stored for Up to Seven Days
NCT00415532	PHASE3	COMPLETED	Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura
NCT00420914	PHASE3	TERMINATED	Strategies for Transfusion of Platelets (SToP)
NCT00501345	PHASE3	TERMINATED	Aspirin in Patients With Myocardial Infarction and Thrombocytopenia
NCT00508820	PHASE3	COMPLETED	An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP
NCT00678587	PHASE3	TERMINATED	Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures
NCT01438840	PHASE3	COMPLETED	Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)
NCT01444417	PHASE3	COMPLETED	Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
NCT01805648	PHASE3	UNKNOWN	Efficacy and Safety Study of Maintenance Treatment With rhTPO in Thrombocytopenic Subjects With ITP
NCT02244658	PHASE3	UNKNOWN	Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia
NCT02389621	PHASE3	COMPLETED	Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures
NCT02444728	PHASE3	TERMINATED	Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE
NCT02487563	PHASE3	COMPLETED	Prospective Study of Patients With Thrombocytopenia Following HSCT
NCT02578901	PHASE3	COMPLETED	American Trial Using Tranexamic Acid in Thrombocytopenia